KIMBERLY BELL: Open Payments
NPI 1962009720 · BRUNSWICK, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$823 in 43 payments from 14 companies in 2025. Trend: 2023 $1,967 · 2024 $229 · 2025 $823
Food & beverage: $823
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $231 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $166 |
| Lilly USA, LLC | 5 | $98 |
| Novo Nordisk Inc | 3 | $63 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $25 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Exact Sciences Corporation | 1 | $18 |
Products named: VRAYLAR, TRINTELLIX, MOUNJARO, REXULTI, FANAPT, LINZESS, JARDIANCE, QULIPTA.
Industry payments across GA — which companies pay providers there.
